PMID: 1203851Jul 1, 1975Paper

Proliferative kinetics of central nervous system (CNS) leukemia

Cancer
A H KuoB D Clarkson

Abstract

The proliferative kinetics of the leukemic cells in the cerebrospinal fluid (CSF) were studied in three adults with CNS leukemia after 18 and 8 months while receiving an intensive treatment regimen. One (J.L.) had acute myeloblastic leukemia and developed CNS disease after 5 years' treatment with arabinosylcytosine and 6-thioguanine. All were in marrow remission at the time of study. G.H. had had no therapy for CNS disease, A.K. had had intrathecal methotrexate 2 months previously, and J.L. had recently completed radiotherapy (1900 R) to the head. An Ommaya reservoir was placed in a lateral ventricle and 3H-thymidine was injected into the resrvoir every 12 hours for 10 days; samples of cells were obtained by lumbar puncture periodically for autoradiography. In all patients the flash 3H-thymidine labeling index (LI) of the leukemic cells was less than 2% (determined in vitro) and the mitotic index less than 0.1%. After 10 days of 3H-thymidine injections in vivo, the LIs of the leukemic cells were 55%, 36%, and 21% in G.H., A.K., and J.L., respectively. These findings indicate that leukemic cells may proliferate very slowly in the CNS, and stress the difficulty of eradicating CNS leukemia with chemotherapeutic agents which are on...Continue Reading

References

Aug 5, 1972·British Medical Journal·R J WestM C Pike
May 1, 1971·The Medical Clinics of North America·B D Clarkson, J Fried
Mar 1, 1970·Cancer·J J Wang, C B Pratt
Nov 7, 1968·The New England Journal of Medicine·R A Ratcheson, A K Ommaya
Mar 1, 1970·Experimental Cell Research·J Fried
Mar 1, 1957·Annals of Internal Medicine·C E WELLS, R T SILVER

❮ Previous
Next ❯

Citations

Jan 1, 1993·Cancer Chemotherapy and Pharmacology·E ChatelutS Kim
Aug 1, 1976·Journal of the Neurological Sciences·H BudkaK Mittermayer
Jan 1, 1984·Cancer Drug Delivery·W A Bleyer
May 1, 1982·Clinical Immunology and Immunopathology·J N VarakisR D Peterson
Aug 28, 2004·Expert Opinion on Pharmacotherapy·Terri S Armstrong, Mark R Gilbert

❮ Previous
Next ❯

Related Concepts

Related Feeds

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.